Clinical trials: Schizophrenia Prodrome
Psychosis Prodrome
Ziprasidone in the Psychosis Prodrome
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
- Trial name
- ZIP (NCT00635700)
- Testing
- ziprasidone
- Where
- 11 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Yale University
Schizophrenia Prodrome
D-serine for the Schizophrenia Prodrome
The purpose of the study is to determine the safety and efficacy of D-serine as an early intervention treatment for the schizophrenia prodrome condition.
- Trial name
- NCT00826202
- Testing
- D-serine
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Prodromal Schizophrenia
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia…
- Trial name
- NCT05052853
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- China Medical University Hospital
Schizophrenia, Bipolar Disorder
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
This study investigates the neuroprotective properties of low-dose lithium in young individuals at ultra-high risk of developping a first psychotic episode.
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT00202306
- Testing
- lithium carbonate
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Melbourne Health
Prodromal Schizophrenia, Prodromal Psychosis
Aripiprazole Treatment of the Prodrome
The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects.
- Trial name
- NCT00169949
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Psychosis
Computer-Aided Learning for Managing Stress
The purpose of this study is to learn whether a new family therapy using computer games with biofeedback might help people at clinical high risk for psychosis and their family members learn to experience less stress and have…
- Trial name
- CALMS (NCT02531243)
- Testing
- CALMS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
Prodromal Schizophrenia
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
Schizophrenia is a severe mental disorder associated with significant impairments in affective, cognitive and social functioning.
- Trial name
- ESPRIT-B1 (NCT03149107)
- Testing
- N-Acetylcysteine, IPPI (Integrated Preventive Psychological Intervention), PSM (Psychological stress management)
- Where
- 10 sites in Germany
- Volunteers
- 48 people
- Sponsor
- University Hospital, Bonn
Psychotic Disorders, Personality Disorders
The Staged Treatment in Early Psychosis Study
A sequential multistage randomised clinical trial (SMART) to produce evidence to guide a step-wise clinical approach for the treatment of ultra high risk patients and reduction of risk for psychosis and other deleterious clinical…
- Conditions
- Psychotic Disorders, Personality Disorders, Clinical High Risk
- Trial name
- STEP (NCT02751632)
- Testing
- Support and Problem Solving Therapy, Cognitive Behavioural Case Management, Fluoxetine
- Where
- 5 sites in Australia
- Volunteers
- 342 people
- Sponsor
- Orygen
Prodromal Schizophrenia
Effects of NAC on Symptoms of CHR Patients
Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with "clinical high-risk" (CHR) symptoms, which are like those of schizophrenia but less severe, and providing psychiatric care to these individuals…
- Trial name
- NCT05142735
- Testing
- N-Acetylcysteine
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Centre for Addiction and Mental Health
Clinical High Risk for Psychosis
Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis
This project is a randomized-controlled trial to test the efficacy of computer-based targeted cognitive training (TCT) versus a placebo intervention of commercial computer games in adolescent/young adults at clinical high risk…
- Trial name
- NCT02404194
- Testing
- Targeted Cognitive Training, Computer Games
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Rush University Medical Center
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)
Brain Imaging in Early Psychosis
This study assesses brain connectivity and function of individuals ages 13-25 at a prodromal or early stage of a psychotic disorder.
- Trial name
- NCT03932188
- Testing
- Mental Health Assessments and Computerized Cognitive Test, MRI scan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia, Prodrome
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis
Early intervention in psychosis might be associated with better outcomes. However, intervention in the pre-psychotic phase has been questioned as, using current criteria, only 20-50% of individuals classified as prodromal develop…
- Trial name
- NCT00396643
- Testing
- Omega 3 fatty acids
- Where
- Austria
- Volunteers
- 81 people
- Sponsor
- Medical University of Vienna
Schizophrenia Prodrome
Ethyl-EPA Treatment of Prodromal Patients
This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.
- Trial name
- NCT00634361
- Testing
- ethyl-eicosapentaenoic acid
- Volunteers
- 7 people
- Sponsor
- Yale University
Schizophrenias, Psychoses
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
The purpose of this study is to determine whether preventative treatment with sarcosine can reduce symptoms and delay/avoid disease progression in individuals defined as being in a prodromal stage of schizophrenia.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00276263
- Testing
- Sarcosine (N-methylglycine)
- Where
- 2 sites in Israel
- Sponsor
- Herzog Hospital
Psychotic Disorders
Dutch Prediction of Psychosis Study
The Dutch Prediction of Psychosis Study (DUPS) is a prospective study of predictors of the transition to psychosis in help-seeking adolescents at high risk for developing a first psychotic episode.
- Trial name
- NCT00188981
- Where
- Netherlands
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Schizophrenia, Psychosis
Aripiprazole Treatment of Prodromal Patients
We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.
- Trial name
- NCT00237874
- Testing
- Aripiprazole
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Yale University
Schizophrenia, Psychoses
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
After one year neuroleptic maintenance treatment in patients with first episode schizophrenia, neuroleptic treatment will be continued vs. stepwise discontinued (randomized design) over a period of 1 year.
- Trial name
- NCT00159120
- Testing
- maintained antipsychotic treatment vs. stepwise drug discontinuation
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia, Psychosis
Psychological Intervention for Persons in the Early Initial Prodromal State
The purpose of this randomized controlled trial is to develop a cognitive behavioral therapy (CBT) for persons with at risk mental states in the early initial prodromal state and to evaluate CBT in comparison to supportive…
- Trial name
- NCT00204087
- Testing
- Cognitive behavioral therapy (CBT), Supportive Counselling (SC)
- Where
- Germany
- Volunteers
- 126 people
- Sponsor
- University of Cologne
Schizophrenia Prodrome
Glycine vs Placebo for the Schizophrenia Prodrome
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.
- Trial name
- NCT00291226
- Testing
- Glycine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University
Prodromal Schizophrenia
Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
Onset of psychotic disorders such as schizophrenia, typically occurs during late adolescence or early adulthood often resulting in chronic social and occupational disability.
- Trial name
- NCT01619319
- Testing
- Cognitive Remediation Therapy, computer games
- Volunteers
- 32 people
- Sponsor
- University of Calgary